Open · 726 days left D National Institutes of Health

Expanding the Target Landscape by Drugging the Undruggable (R21 Clinical Trial Not Allowed)

Funding
Not specified
Deadline
--
Days
--
Hrs
--
Min
--
Sec
Feb 17, 2028
Posted Jun 17, 2025 (248 days ago)
Closes Feb 17, 2028 (in 726 days)

Grant Details

Opportunity Number
PAR-25-442
CFDA / ALN
93.121, 93.242, 93.350, 93.855, 93.865, 93.867
Opportunity Category
Discretionary (D)
Funding Category
Health (HL)
Funding Instrument
Grant (G)
Cost Sharing
No Cost Sharing (No)

Eligibility

State governments (00) County governments (01) City or township governments (02) Special district governments (04) Independent school districts (05) Public and State controlled institutions of higher education (06) Native American tribal governments (Federally recognized) (07) Public housing authorities / Indian housing authorities (08) Native American tribal organizations (11) Nonprofits having a 501(c)(3) status with the IRS (12) Nonprofits without 501(c)(3) status (13) Private institutions of higher education (20) For-profit organizations other than small businesses (22) Small businesses (23) Others (25)

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Description

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit applications for exploratory and early-stage projects that focus on undruggable target classes within intractable human disease. Applicants will identify a human disease relevant undruggable target class and develop a method or agent that is selective for one or more targets within that target class. This NOFO is intended to jumpstart research that demonstrates innovative strategies to modulate targets that cannot be addressed by established therapeutic types, furthering the development of methods and/or agents selective for undruggable target classes.